Altimmune Inc (ALT)
7.61
-0.84
(-9.99%)
USD |
NASDAQ |
Nov 15, 16:00
7.57
-0.04
(-0.53%)
After-Hours: 20:00
Altimmune Research and Development Expense (TTM): 77.94M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 77.94M |
| March 31, 2024 | 70.04M |
| December 31, 2023 | 65.80M |
| September 30, 2023 | 68.07M |
| June 30, 2023 | 69.94M |
| March 31, 2023 | 72.68M |
| December 31, 2022 | 70.54M |
| September 30, 2022 | 71.54M |
| June 30, 2022 | 80.49M |
| March 31, 2022 | 77.77M |
| December 31, 2021 | 74.54M |
| September 30, 2021 | 63.31M |
| June 30, 2021 | 51.14M |
| March 31, 2021 | 54.46M |
| December 31, 2020 | 49.77M |
| September 30, 2020 | 43.70M |
| June 30, 2020 | 35.38M |
| March 31, 2020 | 21.74M |
| December 31, 2019 | 17.77M |
| September 30, 2019 | 17.96M |
| June 30, 2019 | 13.96M |
| March 31, 2019 | 15.93M |
| December 31, 2018 | 18.46M |
| September 30, 2018 | 19.85M |
| June 30, 2018 | 21.03M |
| Date | Value |
|---|---|
| March 31, 2018 | 21.37M |
| December 31, 2017 | 18.41M |
| September 30, 2017 | 16.32M |
| June 30, 2017 | 12.82M |
| March 31, 2017 | 8.945M |
| December 31, 2016 | 7.188M |
| September 30, 2016 | 5.983M |
| June 30, 2016 | 4.708M |
| March 31, 2016 | 4.549M |
| December 31, 2015 | 5.134M |
| September 30, 2015 | 5.753M |
| June 30, 2015 | 6.356M |
| March 31, 2015 | 7.506M |
| December 31, 2014 | 9.320M |
| September 30, 2014 | 11.63M |
| June 30, 2014 | 12.45M |
| March 31, 2014 | 13.48M |
| December 31, 2013 | 15.29M |
| September 30, 2013 | 15.94M |
| June 30, 2013 | 18.52M |
| March 31, 2013 | 20.04M |
| December 31, 2012 | 19.51M |
| September 30, 2012 | 19.29M |
| June 30, 2012 | 19.04M |
| March 31, 2012 | 20.10M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
17.77M
Minimum
Dec 2019
80.49M
Maximum
Jun 2022
59.82M
Average
68.07M
Median
Sep 2023
Research and Development Expense (TTM) Benchmarks
| Eli Lilly and Co | 10.53B |
| Viking Therapeutics Inc | 91.16M |
| Amgen Inc | 5.774B |
| Avid Bioservices Inc | -- |
| NovaBay Pharmaceuticals Inc | 0.064M |